My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Gilead Sciences (NQ:GILD)

126.59 -0.59 (-0.46%)

Streaming Delayed Price Updated: 2:13 PM EST, Nov 19, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2

...

25 26 27 28 29 30 31 32 33

...

68 69 Next >

Nasdaq 100 Alert: 7 Undervalued Tech Stocks Ready to Rocket in 2024 ↗

January 03, 2024

Despite the gains of last year there are still many undervalued tech stocks on the Nasdaq 100 waiting to explode higher in 2024

Via InvestorPlace

10 Health Care Stocks Whale Activity In Today's Session ↗

January 02, 2024

Via Benzinga

The 500 Top Stocks to Buy for 2024, Ranked by AI ↗

December 29, 2023

These are the very best stocks to buy for 2024 for any investor, according to Tom Yeung's MarketMasterAI system.

Via InvestorPlace

$100 Invested In This Stock 20 Years Ago Would Be Worth $1,100 Today ↗

December 25, 2023

Via Benzinga

A Look Into Gilead Sciences Inc's Price Over Earnings ↗

December 22, 2023

Via Benzinga

(GILD) - Analyzing Gilead Sciences's Short Interest ↗

December 18, 2023

Via Benzinga

Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet ↗

December 22, 2023

Each week, Benzinga’s Stock Whisper Index uses a combination of proprietary data and pattern recognition to showcase five stocks that are just under the surface and warrant attention.

Via Benzinga

Gilead Sciences to Present at Upcoming Investor Conference

December 21, 2023

From Gilead Sciences, Inc.

Via Business Wire

U.S. FDA Approves Label Update for Kite’s Yescarta® CAR T-Cell Therapy to Include Overall Survival Data

December 21, 2023

From Gilead Sciences, Inc.

Via Business Wire

3 Biotech Stocks to Buy in the TradeSmith ‘Green Zone’ ↗

December 21, 2023

It's now time to take a look at these three biotech stocks to buy, as each one is currently within TradeSmith's "Green Zone."

Via InvestorPlace

Why Is Immunotherapy-Focused Hookipa Pharma Stock Soaring Today? ↗

December 21, 2023

Gilead Sciences Inc (NASDAQ: GILD) announced on Thursday that it has purchased 15 million shares of HOOKIPA Pharma Inc (NASDAQ: HOOK) for approximately $21.25 million,

Via Benzinga

Why Is Hookipa Pharma (HOOK) Stock Up 81% Today? ↗

December 21, 2023

Hookipa Pharma stock is rising higher on Thursday as investors react to a purchase agreement for 15 million shares of HOOK.

Via InvestorPlace

RedHill's Investigational COVID-19 Drugs Combined With Gilead's Show Effect Against Ebola ↗

December 20, 2023

RedHill Biopharma Ltd (NASDAQ: RDHL) says opaganib and RHB-107 (upamostat) demonstrated robust synergistic effects when combined individually with Gilead Sciences Inc (NASDAQ: GILD) Veklury...

Via Benzinga

QQQ And QQQM ETFs Top Gainers And Laggards Of 2023 ↗

December 20, 2023

This article will look at the top gainers and laggards of the two popular ETFs, which have over $17 billion and $223 billion assets, respectively. The two funds are similar, with the only difference...

Via Talk Markets

Topics ETFs

Why Compugen Shares Are Trading Higher By Over 200%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

December 19, 2023

Shares of Compugen Ltd. (NASDAQ: CGEN) shares rose sharply during Tuesday’s session after Gilead announced an agreement with the company to exclusively license its novel pre-clinical immunotherapy...

Via Benzinga

Why Is Cancer Immunotherapy-Focused Compugen Stock Is Trading Higher Today? ↗

December 19, 2023

Gilead Sciences Inc (NASDAQ: GILD) announced an agreement with Compugen Ltd (NASDAQ: CGEN) to license its pre-clinical antibody program against IL-18 binding protein exclusively, including the

Via Benzinga

Why Is Compugen (CGEN) Stock Up 189% Today? ↗

December 19, 2023

Compugen stock is up on Tuesday as investors in CGEN shares react to an exclusive licensing agreement with Gilead Sciences.

Via InvestorPlace

Gilead and Compugen Announce Exclusive License Agreement for Novel Pre-Clinical Immunotherapy Program

December 19, 2023

From Gilead Sciences, Inc.

Via Business Wire

Patients Regain Weight After They Quit Using Ozempic Rival Zepbound. Here's Why That Makes Eli Lilly Stock an Even Better Buy. ↗

December 16, 2023

Lilly's weight loss drug appears to be on the way to becoming a megablockbuster.

Via The Motley Fool

Pharma’s Frontline: 3 Stocks Driving Revolutionary Drug Development ↗

December 15, 2023

These pharma stock leaders offer revolutionary treatments that could change the world of medicine (and investor's portfolios) for the better.

Via InvestorPlace

NASDAQ:GILD is probably undervalued for the fundamentals it is displaying. ↗

December 12, 2023

Investors should take notice ofGILEAD SCIENCES INC (NASDAQ:GILD)—it offers a great deal for the fundamentals it presents.

Via Chartmill

A Bull Market Is Coming: 1 Stock That Could Rocket 219% Higher in 2024, According to Wall Street ↗

December 12, 2023

There's a huge gap between what the stock market and Wall Street analysts have to say about this often-overlooked growth stock.

Via The Motley Fool

Analyses of Kite’s Yescarta® CAR T-Cell Therapy Support Curative Potential in Patients With Non-Hodgkin Lymphomas

December 11, 2023

From Gilead Sciences, Inc.

Via Business Wire

New Analyses Presented at ASH 2023 Support the Potential Long-Term Response and Safety of Kite’s Tecartus® in Patients With Aggressive Blood Cancers

December 11, 2023

From Gilead Sciences, Inc.

Via Business Wire

Long-Term Data for Kite’s Yescarta® CAR T-Cell Therapy Presented at ASH 2023 Demonstrate High Rate of Durable Response in Patients With High-Risk Large B-Cell Lymphoma

December 11, 2023

From Gilead Sciences, Inc.

Via Business Wire

10 Health Care Stocks With Whale Alerts In Today's Session ↗

December 11, 2023

Via Benzinga

Gilead Sciences Battles Rising Threat of Drug Counterfeiting, Initiates Legal Actions ↗

December 11, 2023

Gilead Sciences Inc (NASDAQ: GILD) faces a severe threat from the rise in drug counterfeiting, a global issue highlighted by the World Health Organization's staggering estimate of up to $431 billion...

Via Benzinga

Gilead Named to Dow Jones Sustainability World Index for Third Consecutive Year

December 11, 2023

From Gilead Sciences, Inc.

Via Business Wire

This 1 Emerging Risk Could Be a Problem for These 3 Big Pharma Stocks ↗

December 10, 2023

Regulators are already on the case, and their findings will have financial impacts.

Via The Motley Fool

3 biotech powerhouses poised to thrive amid sector rebound

December 08, 2023

If the newfound support and uptrend in the biotech sector last, as the new year quickly approaches, the biotech sector could shift from lagger to leader.

Via MarketBeat

Topics ETFs

< Previous 1 2

...

25 26 27 28 29 30 31 32 33

...

68 69 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.